Anticancer Drugs Axitinib Oncology Pharmacology Physiotherapy

Axitinib (Mechanism of Action)

In this article we will discuss Axitinib (Mechanism of Action).

In this article, we will discuss Axitinib (Mechanism of Action). So, let’s get started.

Mechanism of Action

Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. VEGF-mediated endothelial cell proliferation and survival were inhibited by axitinib in vitro and in mouse models. Axitinib was shown to inhibit tumor growth and phosphorylation of VEGFR-2 in tumor xenograft mouse models.


The effect of a single oral dose of Axitinib (5 mg) in the absence and presence of 400 mg
ketoconazole on the QTc interval was evaluated in a randomized, single-blinded, two-way crossover study in 35 healthy subjects. No large changes in mean QTc interval (i.e., >20 ms) from placebo were detected up to 3 hours post-dose. However, small increases in mean QTc interval (i.e., <10 ms) cannot be ruled out.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.